MedTrace Logo

Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs

NCT03812939 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2019-01-23

No results posted yet for this study

Summary

This study evaluates the efficacy of Long-acting Somastostatin analogs as treatment for type I gastric neuroendocrine tumors.

Conditions

  • Gastric NET

Interventions

DRUG

Octreotide

Patients will receive 6-12 monthly injections every 28 (+/- 3) days.

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2019-12-31
Completion
2020-12-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03812939 on ClinicalTrials.gov